113 related articles for article (PubMed ID: 4426048)
1. Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.
Buckner CD; Briggs R; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Storb R; Thomas ED
Cancer Chemother Rep; 1974; 58(5 Pt 1):697-703. PubMed ID: 4426048
[No Abstract] [Full Text] [Related]
2. Chemotherapy of ovarian cancer with melphalan.
Rutledge F
Clin Obstet Gynecol; 1968 Jun; 11(2):354-66. PubMed ID: 4971815
[No Abstract] [Full Text] [Related]
3. Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after falure on melphalan.
Twiggs LB; Morrow CP
Cancer Treat Rep; 1977 Oct; 61(7):1369-71. PubMed ID: 589602
[No Abstract] [Full Text] [Related]
4. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms.
Buckner CD; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Paulsen A; Storb R; Thomas ED
Cancer Chemother Rep; 1974; 58(5 Pt 1):709-14. PubMed ID: 4609599
[No Abstract] [Full Text] [Related]
5. [Treatment with large doses of cyclophosphamide of breast cancer with metastases to solid viscera].
Chrapowicki A
Wiad Lek; 1971 Dec; 24(24):2323-6. PubMed ID: 5139720
[No Abstract] [Full Text] [Related]
6. Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
Lalos O; Frankendal B; Rudolphi O
Ann Chir Gynaecol; 1977; 66(3):131-134. PubMed ID: 327909
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant chemotherapy in ovarian carcinoma].
Conte PF; Bruzzone M; Carnino F
Minerva Ginecol; 1984 Apr; 36(4):191-4. PubMed ID: 6540425
[No Abstract] [Full Text] [Related]
9. [Results of a cyclophosphamide therapy in genital and mammary carcinomas].
Naumann R
Zentralbl Gynakol; 1970 May; 92(22):700-2. PubMed ID: 5284155
[No Abstract] [Full Text] [Related]
10. [Endoxan in ovarian cancer].
Campodónico I; Soldati A; Rodríguez A
Rev Chil Obstet Ginecol; 1974; 39(3):87-9. PubMed ID: 4620179
[No Abstract] [Full Text] [Related]
11. Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide.
Young RC; Canellos GP; Chabner BA; Schein PS; Hubbard SP; DeVita VT
Gynecol Oncol; 1974 Dec; 2(4):489-97. PubMed ID: 4376998
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide in the treatment of ovarian cancer.
Decker DG; Mussey E; Malkasian GD; Johnson CE
Clin Obstet Gynecol; 1968 Jun; 11(2):382-400. PubMed ID: 4879372
[No Abstract] [Full Text] [Related]
13. Short-term administration of cytembena and cyclophosphamide to patients with gynaecological carcinoma. (Evaluation ff laboratory examinations).
Jandová A; Skoda V; Novotná J; Pezlarová I; Pick P
Neoplasma; 1971; 18(2):197-218. PubMed ID: 5280733
[No Abstract] [Full Text] [Related]
14. Comparison of cytostatic activities of cytembena and cyclophosphamide during short-term administration to women with gynaecological carcinoma.
Skoda V; Jandová A; Novotná J
Neoplasma; 1970; 17(2):175-81. PubMed ID: 5269150
[No Abstract] [Full Text] [Related]
15. The role of postoperative alkylating agent therapy in early-stage epithelial ovarian cancer.
Mackintosh J; Buckley CH; Tindall VR; Lind MJ; Anderson H; Crowther D
Br J Obstet Gynaecol; 1989 Mar; 96(3):353-7. PubMed ID: 2713294
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
Curtis JE
Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
[No Abstract] [Full Text] [Related]
17. High-dose cyclophosphamide (NSC-26271) for recurrent or progressive ovarian adenocarcinoma.
Piver MS; Barlow JJ; Chung WS
Cancer Chemother Rep; 1975; 59(6):1157-8. PubMed ID: 769956
[No Abstract] [Full Text] [Related]
18. Effect of nandrolone phenylpropionate (NSC-23162e) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): a clinical trial.
Burn JI; Cooke WM
Cancer Chemother Rep; 1974; 58(6):867-70. PubMed ID: 4615786
[No Abstract] [Full Text] [Related]
19. The treatment of advanced ovarian carcinoma with high dose, intravenous cyclophosphamide.
Geisler HE; Minor JR; Eastlund ME
Gynecol Oncol; 1976 Mar; 4(1):43-52. PubMed ID: 992477
[No Abstract] [Full Text] [Related]
20. Factors influencing ovarian cancer survival after chemotherapy.
Webb MJ; Malkasian GD; Jorgensen EO
Obstet Gynecol; 1974 Oct; 44(4):564-70. PubMed ID: 4413425
[No Abstract] [Full Text] [Related]
[Next] [New Search]
